Axokine: More time will tell

Regeneron Pharmaceuticals Inc. is a step closer to cashing in on its serendipitous discovery that Axokine modified ciliary neurotrophic factor induces weight loss, as Phase II results announced last week showed the protein's ability to cause weight loss in severely obese patients. The next hurdle for Axokine will be to show that results can be sustained at one year with minimal side effects.

CNTF is a distant relative of leptin. It activates leptin-like pathways in the hypothalamus but works in forms of obesity resistant to leptin treatment. REGN created a truncated and modified

Read the full 925 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE